Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Surg Oncol. 2012 Mar;105(3):316-22. doi: 10.1002/jso.22078. Epub 2011 Aug 31.
Gastric cancer (GC) in Israel remains incompletely characterized. The aim of this study was to define the clinical and pathological characteristics of GC in Israel and to compare them to the general Western population.
This is a retrospective analysis of 461 consecutive GC patients treated at a single institution between 1995 and 2007. Epidemiological and clinical-pathological data were retrieved from the patients' medical files and the institutional electronic database and analyzed using standard statistical methods.
Epidemiology, clinical manifestations, histopathological findings, clinical course, and prognostic factors for disease outcome were all similar to those reported in the Western literature. Findings unique to the Israeli population included: (1) rarity of GC-associated risk factors; (2) increased GC incidence in Ashkenazi Jews; (3) high incidence of second primary malignancy and family history of cancer; and (4) no dominancy of proximal GCs.
There do not appear to be any major differences in the biology or clinical manifestations of GC in Israel. Western recommendations for diagnosis and treatment of GC may therefore be applied to the Israeli patient population.
以色列的胃癌(GC)仍未得到充分描述。本研究旨在确定以色列 GC 的临床和病理特征,并将其与一般西方人群进行比较。
这是对 1995 年至 2007 年在一家机构接受治疗的 461 例连续 GC 患者进行的回顾性分析。从患者的病历和机构电子数据库中检索了流行病学和临床病理数据,并使用标准统计方法进行了分析。
流行病学、临床表现、组织病理学发现、临床病程和疾病结局的预后因素均与西方文献报道的相似。以色列人群特有的发现包括:(1)GC 相关危险因素罕见;(2)在阿什肯纳兹犹太人中 GC 发病率增加;(3)第二原发恶性肿瘤和癌症家族史的发生率高;(4)近端 GC 不占优势。
以色列 GC 的生物学或临床表现似乎没有任何重大差异。因此,西方 GC 的诊断和治疗建议可能适用于以色列患者人群。